Peptide science did not begin with modern social media or research-market vials. Peptides, peptide hormones and peptide/protein medicines have a long biomedical history. That history is useful only when it is accurately sourced and does not blur old established medicines with modern investigational compounds.
Insulin research becomes a landmark therapeutic milestone
Banting, Best, Collip and Macleod’s work in Toronto led to clinical insulin treatment in 1922. The 1923 Nobel Prize in Physiology or Medicine recognised Banting and Macleod. Insulin is a protein/polypeptide hormone rather than a reason to treat every “peptide” as one category, but it is a foundational example of amino-acid-chain biology becoming medicine.
Du Vigneaud and the first synthesis of a polypeptide hormone
Vincent du Vigneaud received the 1955 Nobel Prize in Chemistry for work on biologically important sulphur compounds, especially the first synthesis of a polypeptide hormone. His work included oxytocin synthesis and helped demonstrate that biologically active peptide hormones could be chemically synthesised.
Protein sequence becomes knowable
Frederick Sanger determined the amino-acid sequence of insulin, a decisive advance in understanding how amino-acid residues are ordered in biological chains. He received the 1958 Nobel Prize in Chemistry for work on protein structure, especially insulin.
Solid-phase peptide synthesis changes laboratory chemistry
Bruce Merrifield developed solid-phase peptide synthesis, allowing peptide chains to be assembled iteratively while attached to a solid support. His work transformed practical peptide synthesis and was recognised with the 1984 Nobel Prize in Chemistry.
Recombinant human insulin reaches US approval
The FDA approved Humulin on 28 October 1982. FDA’s history describes it as the first biosynthetic human insulin product and the first approved medical product produced using recombinant-DNA technology — a milestone in modern biologic manufacturing.
Peptide engineering expands
Medicinal chemistry increasingly modifies native signalling molecules to change stability, receptor activity, half-life and delivery. Modern incretin medicines illustrate how an endogenous signalling pathway can lead to engineered peptide analogues with large clinical trial programmes and highly specific product approvals.
Approved medicines and investigational multi-agonists coexist
Semaglutide and tirzepatide are examples of regulator-authorised peptide-based medicines in defined products and indications, while compounds such as retatrutide remain investigational despite late-stage clinical evidence. The lesson is not that “peptides work”; it is that each entity needs its own evidence and regulatory record.
What this history does not prove
A long history of peptide science does not validate a specific modern research-market compound, blend, formulation or claim. WhichPeps uses history for orientation, then returns to the evidence for the exact canonical entity.